13F Holdings
中文EN

BLCO Bausch & Lomb Corp

Ophthalmic Goods · NYSE · SEC CIK 1860742 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.9%
TTM net income YoY63.6%
TTM EPS YoY62.8%
Revenue 3-yr CAGR10.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin7.1%
Net margin-2.0%
FCF margin4.7%
EBITDA margin14.5%

Returns

ROE-1.7%
ROA-0.8%
ROIC (approx.)2.8%
Asset turnover0.39x

Leverage & solvency

Liabilities / assets53.4%
Debt / equity0.78x
Current ratio1.56x
Interest coverage1.00x

Cash quality & payout

Operating cash flow / net income-4.99x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue5.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$5.10B$4.79B$4.15B$3.77B$3.77B
R&D expense$371.00M$343.00M$324.00M$307.00M$271.00M
SG&A expense$2.23B$2.08B$1.74B$1.48B$1.39B
Operating income$113.00M$162.00M$130.00M$207.00M$329.00M
Interest expense$421.00M$399.00M$283.00M$146.00M$0
Pretax income-$317.00M-$234.00M-$166.00M$73.00M$318.00M
Income tax$35.00M$71.00M$82.00M$58.00M$125.00M
Net income-$360.00M-$317.00M-$260.00M$6.00M$182.00M
EBITDA$534.00M$598.00M$512.00M$586.00M$744.00M
EPS (basic)-1.02-0.90-0.740.020.52
EPS (diluted)-1.02-0.90-0.740.020.52
Weighted avg. shares (diluted)353.80M351.80M350.50M350.20M350.00M
Balance sheet
Cash & equivalents$383.00M$316.00M$334.00M$380.00M$177.00M
Receivables$1.22B$1.03B$839.00M$724.00M$721.00M
Inventory$976.00M$1.04B$1.03B$628.00M$572.00M
Current assets$2.98B$2.79B$2.74B$2.14B$1.64B
PP&E, net$1.76B$1.49B$1.39B$1.30B$1.23B
Goodwill$4.76B$4.52B$4.58B$4.51B$4.59B
Intangibles$3.28B$3.49B$3.59B$2.06B$2.26B
Total assets$14.02B$13.47B$13.44B$11.14B$10.82B
Current liabilities$1.92B$1.74B$1.58B$1.30B$1.10B
Short-term debt$28.00M$40.00M$30.00M$25.00M$0
Long-term debt$5.02B$4.74B$4.53B$2.41B$0
Total debt$5.05B$4.78B$4.56B$2.44B$0
Total liabilities$7.50B$6.92B$6.52B$4.04B$1.42B
Shareholders' equity$6.45B$6.47B$6.85B$7.03B$9.33B
Net debt$4.67B$4.47B$4.23B$2.06B-$177.00M
Shares outstanding354.21M352.40M350.91M350.00M350.00M
Cash flow statement
Operating cash flow$283.00M$232.00M-$17.00M$345.00M$873.00M
Capital expenditure$349.00M$291.00M$181.00M$175.00M$193.00M
Free cash flow-$66.00M-$59.00M-$198.00M$170.00M$680.00M
Investing cash flow-$455.00M-$412.00M-$2.11B-$215.00M-$214.00M
Financing cash flow$225.00M$178.00M$2.08B$81.00M-$712.00M
Depreciation & amortization$421.00M$436.00M$382.00M$379.00M$415.00M
Stock-based compensation$149.00M$92.00M$74.00M$62.00M$62.00M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.